Trial Profile
The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 mcg Ethinyl Estradiol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/norelgestromin (Primary) ; Ethinylestradiol/norgestimate
- Indications Pregnancy
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 May 2007 New trial record.